Intrinsic thermodynamics of ethoxzolamide inhibitor binding to human carbonic anhydrase XIII
© Baranauskienė and Matulis; licensee BioMed Central Ltd. 2012
Received: 29 November 2011
Accepted: 1 May 2012
Published: 7 June 2012
Human carbonic anhydrases (CAs) play crucial role in various physiological processes including carbon dioxide and hydrocarbon transport, acid homeostasis, biosynthetic reactions, and various pathological processes, especially tumor progression. Therefore, CAs are interesting targets for pharmaceutical research. The structure-activity relationships (SAR) of designed inhibitors require detailed thermodynamic and structural characterization of the binding reaction. Unfortunately, most publications list only the observed thermodynamic parameters that are significantly different from the intrinsic parameters. However, only intrinsic parameters could be used in the rational design and SAR of the novel compounds.
Intrinsic binding parameters for several inhibitors, including ethoxzolamide, trifluoromethanesulfonamide, and acetazolamide, binding to recombinant human CA XIII isozyme were determined. The parameters were the intrinsic Gibbs free energy, enthalpy, entropy, and the heat capacity. They were determined by titration calorimetry and thermal shift assay in a wide pH and temperature range to dissect all linked protonation reaction contributions.
Precise determination of the inhibitor binding thermodynamics enabled correct intrinsic affinity and enthalpy ranking of the compounds and provided the means for SAR analysis of other rationally designed CA inhibitors.
Carbonic anhydrases (CAs) are zinc-containing metalloenzymes that catalyze reversible hydration of carbon dioxide to the bicarbonate ion. The enzyme has been studied since 1930s and has become a classical model protein in biochemistry [1–5]. Recently, the interest in the enzyme has risen again. It is known now that CAs are present both in prokaryotes and eukaryotes, and are encoded by five gene families: the α-CAs (predominantly in vertebrates), the β-CAs (bacteria, algae, other), γ-CAs (archaea), δ-CAs and ζ-CAs (in some marine diatoms) [6–8]. All human CAs belong to the alpha class. There are 12 catalytically active human CA isoforms: I, II, III, VII, and XIII are cytosolic, IV, IX, XII, and XIV are associated with cell membrane, VA and VB occur in mitochondria, and VI is secreted. There are 3 CA-related proteins VIII, X, and XI that are devoid of catalytic activity due to the absence of zinc. Human CAs were reviewed in detail, including their widely different catalytic and kinetic properties, response to inhibitors, expression patterns, and application for drug design .
Human CAs are widely distributed in many tissues and organs. The CAs play a crucial role in CO2 and HCO3- transport, pH and CO2 homeostasis, electrolyte secretion, biosynthetic reactions, and tumor progression. Therefore the CAs became interesting targets for pharmaceutical research . However, the main drawback of available compounds is insufficient selectivity towards particular CA isozyme.
Rational design of compounds with desired binding properties requires detailed investigation of the structure-activity relationships (SAR) of the newly designed compounds. Both the thermodynamics of binding and the structure of protein-ligand complex are required for detailed understanding of the reaction and search and rational design of drug-like molecules. It is important to go beyond the determination of the K i and determine the full thermodynamic profile, especially the enthalpy of binding . Here we describe the intrinsic thermodynamic analysis of well known CA inhibitors, ethoxzolamide (EZA), trifluoromethanesulfonamide (TFMSA), and acetazolamide (AZM) binding to human CA XIII isozyme.
Human CA XIII isozyme has been characterized . The enzyme expression in human tissues showed that CA XIII is found in several organs including the thymus, kidney, submandibular gland, small intestine, and most notably in reproductive organs suggesting involvement in the fertilization process [7, 11]. The CO2 hydration activity showed CA XIII to be a catalyst of medium efficiency . Inhibition profiles demonstrated that CA XIII is similar to CA II . The crystal structure of hCA XIII and its complex with acetazolamide has been solved providing crucial structural data for inhibitor SAR .
Manuscripts reporting novel CA inhibitors usually list only the observed thermodynamic parameters of binding or the observed inhibition constants (K i ) [8, 14–16]. Such data is useful for the design of novel inhibitors. However, it should not be used for the SAR and correlations with structures. Proper SAR requires correlation of structures only with the intrinsic binding parameters that are dissected from linked reactions occurring simultaneously with the binding reaction. Most often, such linked reactions are protonation-deprotonation reactions occurring upon ligand binding. In the case of CAs, both the inhibitor, and the CA molecule may or may not exhibit a linked protonation reaction upon inhibitor binding. Observed and intrinsic binding parameters coincide only in some rare cases when the inhibitor is deprotonated and the zinc-linked hydroxide anion is protonated. Such situation is possible only with some CA isozymes and only with the inhibitors with the pK a s significantly below 7. Most sulfonamide inhibitors have their pK a s in the range between 8 and 11. Therefore, only small fraction of the compound is in the form that binds the protein. Despite the fact that the linked protonation reactions are largely worked-out, they are rarely used in the SAR of CA inhibitors [17–19].
By ‘intrinsic’ we mean the parameters that describe actual binding reaction. In the case of sulfonamide inhibitor binding to CAs, the actual binding components are the deprotonated sulfonamide and the CA with protonated Zn-bound water molecule. Only these two forms bind each other. However, in most cases, other forms are the most abundant in solution – sulfonamide is usually protonated and the CA contains unprotonated water molecule. The concentration of the forms that actually bind is small relative to other forms and it takes energy to convert them to active forms. The observed binding energy is therefore diminished and does not resemble true (intrinsic) energetic parameters.
Determination of the intrinsic binding constant (K b , Gibbs free energy Δ b G intr ), intrinsic enthalpy (Δ b H intr ), intrinsic entropy (Δ b S intr ), and the intrinsic heat capacity of binding (Δ b C p_intr ) requires significant effort and a number of measurements at various pHs and temperatures. Here we use isothermal titration calorimetry (ITC) and thermal shift assay (TSA, also called ThermoFluor®, differential scanning fluorimetry) to measure inhibitor binding to CAs. ITC has been routinely used to measure ligand-protein binding thermodynamics . However, it is not appropriate for determining weak (millimolar) or very tight dissociation constants (subnanomolar K d s require displacement ITC ) and consumes extensive amounts of protein and time. In contrast, TSA is a rapid screening method used in pharmaceutical industry for the identification of binders and requires lower amounts of protein [22–27]. The method is based on the protein melting temperature (T m ) shift that occurs upon ligand binding. The T m is observed by following intrinsic or extrinsic fluorescence changes upon heat-induced protein unfolding. The employment of two techniques to determine binding reactions reduces the error of the measurements. Here we apply both techniques to determine the observed binding parameters and then estimate the intrinsic parameters that could be used for CA inhibitor SAR analysis.
Ethoxzolamide and other inhibitor binding to hCA XIII by ITC
In order to draw any thermodynamic energetics-structure correlations, the experimentally determined binding parameters must be intrinsic. In other words, all binding-linked contributing reactions must be accounted for and dissected from the reaction of interest. The most common protein-ligand binding-linked reactions are protonation or deprotonation. Sulfonamide inhibitor binding reaction to carbonic anhydrase (CA) is linked to at least two reactions, the protonation of zinc-bound hydroxide anion, and deprotonation of sulfonamide inhibitor group.
Similarly to the effect of pH, the effect of buffer is seen from Figure 2c where the observed enthalpy of binding is approximately 40% more exothermic in phosphate than in TRIS buffer. The observed enthalpies of binding vary linearly with the enthalpy of buffer protonation. Figure 2d shows EZA and trifluoromethanesulfonamide (TFMSA) binding at pH 7.0 to hCA XIII in various buffers: phosphate (5.1), PIPES (11.5), MES (15.5), HEPES (21.0), MOPS (22.2), imidazole (36.6), and TRIS (47.4) (in the order of increasing buffer protonation enthalpy in kJ/mol at 25°C in the brackets). Here, the slope of the dependence shows the net number of uptaken or released protons upon binding. The positive slope indicates that the protons are taken up from buffer upon ligand binding while the negative slope shows that the protons are given from the protein and /or ligand to the buffer. It is clear that EZA binding is linked to protonation reactions and the protons are released from the protein-ligand system to the buffer while TFMSA binding appears to be either not linked to protonation or the net number is approximately equal to zero.
Figure 2e shows the observed EZA binding enthalpy dependence on temperature at pH 7.0. The dependence is linear within the error margin of the enthalpy determination yielding the observed heat capacity of EZA binding equal to −980 J/(mol × K).
Observed thermodynamic parameters of EZA binding to hCA XIII in phosphate and TRIS buffers are listed as a function of pH as determined by ITC at 25°C
K b_obs , M-1
Δ b G obs , kJ/mol
Δ b H obs , kJ/mol
TΔ b S obs , kJ/mol
Δ b S obs , kJ/(mol × K)
EZA - hCA XIII binding in phosphate buffer
1.70 × 107
1.17 × 108
4.96 × 108
3.33 × 108
EZA - hCA XIII binding in TRIS buffer
5.95 × 106
2.10 × 108
8.69 × 108
2.27 × 108
ITC is a very good method to determine intrinsic binding parameters and dissect the linked protonation reactions. However, it must be used with great care. The main limitation is that the method has rather narrow window of experimentally determinable binding constants. If protein concentration is 10 μM, and if c parameter (the product of binding constant and protein concentration) is to be between 5 and 500, then the accurate observed K b_obs could be obtained only from 5 × 105 to 5 × 107 M-1. As seen in Table 1, the binding is tighter at many conditions. Therefore, an additional independent method is necessary to accurately determine the intrinsic binding constant K b_intr , and the derived thermodynamic parameters such as the Gibbs free energy and the entropy of binding.
EZA and TFMSA binding to hCA XIII by TSA and DSC
Similar T m shift is observed by DSC (Figure 4c). Addition of EZA shifted the T m by more than 10°C and the enthalpy of unfolding (the area under the DSC peak) increased due to the positive heat capacity of hCA XIII unfolding. In the absence of ligand, the hCA XIII exhibited the T m equal to 58.6°C and the enthalpy of unfolding was equal to 573 ± 150 kJ/mol at pH 7.0. In the presence of 0.5 mM EZA the peak shifted to 72.4°C and the enthalpy of unfolding increased to 937 kJ/mol.
Dissection of binding-linked protonation reactions
Thermodynamic parameters of the protonation of inhibitor sulfonamide group and hCA XIII zinc-bound hydroxide anion at 25°C
Δ b_proton H, kJ/mol
K a , M
Δ b_proton G, kJ/mol
TΔ b_proton S, kJ/mol
Δ b_proton S, J/(mol × K)
Δ b_proton C p , J/(mol × K)
1.0 × 10-8
5.6 × 10-7
5.0 × 10-8
5.6 × 10-9
The pK a of ethoxzolamide protonation has been previously determined to be equal to 8.0 . The enthalpy of ethoxzolamide deprotonation has been determined by ITC (Figure 6). The pK a s and enthalpies of other widely used inhibitors, including acetazolamide (AZM), methazolamide, dichlorophenamide, trifluoromethanesulfonamide (TFMSA), and p-amino benzene sulfonamide, have been previously determined .
Intrinsic binding parameters
The intrinsic thermodynamic binding parameters of deprotonated inhibitor anion to the protonated form of zinc-bound water molecule of hCA XIII at 25°C
Δ b H intr , kJ/mol
K b_intr , M-1
Δ b G intr , kJ/mol
TΔ b S intr , kJ/mol
Δ b S intr , J/(mol × K)
Δ b C p_intr , J/(mol × K)
1.8 × 109
4.6 × 107
1.9 × 107
The intrinsic binding constants were greater than the observed ones and were equal to 1.8 × 109 M-1 for EZA and 4.6 × 107 M-1 for TFMSA. The enthalpies of binding were respectively equal to −42.1 and −33.5 kJ/mol. The entropies of binding of both inhibitors had a relatively small but positive contribution equal to 10.7 and 10.2 kJ/mol respectively. The binding process is therefore primarily enthalpy-driven and slightly supported by favorable entropic contribution for both inhibitors.
The intrinsic heat capacity of EZA binding to hCA XIII was determined to be −750 J/(mol × K). This is significantly different from the observed heat capacity of EZA binding at pH 7.0 (Figure 2e) equal to −980 J/(mol × K). The difference between observed and intrinsic parameters is important even for the heat capacity and again illustrates the importance of determining the intrinsic parameters.
The intrinsic binding thermodynamic parameters of acetazolamide (AZM) to hCA XIII were estimated by applying the same additivity principles from the data at single pH 7.0 and single temperature. The pK a and enthalpy of the protein protonation were determined using EZA and TFMSA as ligands while the pK a and enthalpy of AZM protonation have been previously determined  (Table 2). Using these parameters in the additivity scheme yields the intrinsic parameters listed in Table 3. Interestingly, binding of AZM had the largest intrinsic exothermic enthalpy of the three inhibitors, but the Gibbs free energy was least exergonic. Therefore, the entropic contribution to the AZM binding reaction was negative.
Detailed analysis with numerous ITC experiments at various pHs is needed to be performed just once with one selected strongly-binding inhibitor. In this study, such inhibitor was selected to be EZA. To confirm the intrinsic binding parameters, additional ligand, TFMSA was studied and showed that the same set of parameters is suitable to describe the binding of this ligand. The binding parameters of the third ligand, AZM, were determined from experiments at single pH 7.0. All other sulfonamide inhibitors to be designed and studied in the future will only need one set of ITC and TSA experiments at a single pH. In addition, the pK a and enthalpy of the sulfonamide protonation will have to be determined.
Most studies, describing novel sulfonamide inhibitors listed only the observed K d s and/or K i s. [8, 14, 28, 32, 33]. The observed parameters provide estimates of the potency of each inhibitor at particular experimental conditions. However, these parameters are not suitable for the SAR-type studies and may mislead the rational design of novel inhibitors. Quite often, the observed K d s may differ by 3 orders of magnitude, but the intrinsic K d s may be comparable. In such cases, one may erroneously assign the greater observed potency to the protein-ligand interaction surface, while the true reason is simply the difference in pK a of the ligand sulfonamide group.
A good example is the comparison of intrinsic and observed K d s of TFMSA and methanesulfonamide interaction with CA II. Their observed K i s and K d s at pH 7.0 are 2 × 10-9 M and 3 × 10-4 M, respectively. However, their intrinsic K d s are 1.9 × 10-9 M and 2.4 × 10-8 M, respectively. The difference between the observed and intrinsic parameters for TFMSA is quite negligible, but for methanesulfonamide is very large. Based on the observed parameters, one could erroneously conclude that the three fluorine atoms increase the inhibition constant by 150 000 times as compared to methane group. In reality, the fluorines only increase the intrinsic binding constant by only 12 times. In other words, the fluorines bind to CA II 12 times stronger than methane hydrogens and this value could be used for the SAR of the fluorines. The remaining part is due to the difference in compound pK a s and the available fractions of anionic sulfonamide at pH 7.0. Therefore, the studies presenting novel inhibitors should either determine the intrinsic parameters of binding or avoid pursuing observed K d /K i -based SAR analysis .
Acetazolamide is one the most widely used inhibitor to compare results between various laboratories. Here we determined the observed K d for AZM binding to hCA XIII at pH 7.0 by both ITC and TSA to be 113 ± 30 nM. The intrinsic K d is then calculated to be 53 nM. This insignificant difference from the observed value is due to the relatively low pK a of AZM (7.30). Large fraction of AZM is in its active deprotonated form at pH 7.0. Supuran with coworkers lists the observed K i of AZM binding to murine isozyme mCA XIII to be equal to 17 nM . The difference may be due to the different organism - human and murine isozymes.
The example of AZM shows the case when intrinsic and observed binding parameters are quite similar and may appear to be within the error region. However, most CA inhibitors have their pK a s in the range between 9 and 11. Such inhibitors would exhibit observed K d s at pH 7.0 that are 2 to 4 orders of magnitude different from the intrinsic K d s. Large hidden differences in their pKas could mislead the researchers to the erroneous reasons of the binding potency.
Ethoxzolamide binding to hCA XIII is linked to several protonation reactions that must be dissected in order to estimate the intrinsic Gibbs free energies, enthalpies, entropies, and heat capacities of binding. Observed binding parameters for at least one inhibitor should be determined in a wide pH range. Combination of both methods, ITC and TSA is desired when the observed K d s are near the limit of precise determination range of ITC. Intrinsic enthalpy of EZA binding is −42.1 kJ/mol, intrinsic Gibbs free energy −52.8, and the intrinsic entropy of binding is 35.9 J/(mol × K).
Ethoxzolamide (EZA) was purchased from Aldrich (Milwaukee, WI, USA), trifluoromethanesulfonamide (TFMSA) was purchased from Alfa Aesar. Human carbonic anhydrase XIII (hCA XIII) was expressed in Escherichia coli and purified as previously described . Ethics approval: no human or animal samples or live animals were used in this research.
Isothermal titration calorimetry (ITC)
ITC experiments were performed using a VP-ITC instrument (Microcal, Inc., GE-Healthcare, Northampton, MA, USA). For ligand-protein binding experiments 5–20 μM (usually 10) protein solution in the cell and 50–200 μM (usually 100) ligand solution in the syringe were used. A typical experiment consisted of 25–30 injections (usually 25), 10 μL each, with 3–5 min (usually 4 min) intervals between injections. Experiments were performed at different temperatures in various buffers containing 50 mM NaCl and 0.5-2% DMSO concentration. All experiments were repeated at least twice. For the determination of ligand binding at various pHs, the solution pH was carefully checked in the presence of protein and ligand, in the cell and syringe, respectively. The buffering capacity is low at some pH values (for example, phosphate at pH 9.5 or TRIS at pH 5.5) and had to be carefully adjusted with acidic or basic components of the buffer.
Thermal Shift Assay (TSA)
TSA experiments were performed with Corbett Rotor-Gene 6000 (QIAGEN Rotor-Gene Q) instrument using the blue channel (excitation 365 ± 20, detection 460 ± 15 nm), applying the heating rate of 1°C/min. Usually, the samples contained 20 μL of 10 μM protein, 0–200 μM ligand, 50 μM 8-anilino-1-naphthalene sulfonate, 50 mM sodium phosphate at pH 7.0, 50 mM NaCl , and 2% DMSO. The pH dependence of the K b was determined in the universal buffer containing 50 mM sodium phosphate, 50 mM sodium acetate, and 25 mM sodium borate. The fluorescence and ligand dosing curves were fit as previously described [27, 28]. TSA experiments were repeated at least three times. The standard deviation was below 10%.
Differential Scanning Calorimetry (DSC)
DSC experiments were performed using MC-2 Scanning Calorimeter (Microcal, Inc., GE-Healthcare, Northampton, MA, USA). The samples of 1.2 mL (cuvette volume) contained 50 μM hCA XIII, 0 or 500 μM ethoxzolamide, 50 mM sodium phosphate (pH 7.0), and 50 mM NaCl. A scan rate of 1°C /min was used.
Intrinsic heat capacity of ligand binding
Gibbs free energy of protonation
Intrinsic Gibbs free energy of binding
Gibbs free energy of binding
Heat capacity of protonation
Enthalpy of protonation
Intrinsic enthalpy of binding
Observed enthalpy of binding
Entropy of protonation
Intrinsic entropy of binding
Observed entropy of binding
Isothermal titration calorimetry
Acidity constant (proton dissociation, deprotonation constant)
Intrinsic binding constant
Observed binding constant
Number of protons in a protonation/deprotonation reaction
TRIS (Trizma) buffer
Thermal shift assay.
This research was funded by a grant (No. LIG-16/2010) from the Research Council of Lithuania.
- Stadie W, O’Brien H: The catalysis of the hydration of carbon dioxide and dehydration of carbonic acid by an enzyme isolated from red blood cells. J Biol Chem. 1933, 103: 521-529.
- Khalifah RG: Carbon dioxide hydration activity of carbonic anhydrase: paradoxical consequences of the unusually rapid catalysis. Proc Natl Acad Sci U S A. 1973, 70 (7): 1986-1989.View Article
- Silverman DN, Lindskog S: The catalytic mechanism of carbonic anhydrase: implications of a rate-limiting proteolysis of water. Acc Chem Res. 1988, 21: 30-36.View Article
- Sly WS, Hu PY: Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem. 1995, 64: 375-401.View Article
- Liljas A, Laurberg M: A wheel invented three times. The molecular structures of the three carbonic anhydrases. EMBO Rep. 2000, 1: 16-17.View Article
- Supuran CT: Carbonic anhydrase inhibition with natural products: novel chemotypes and inhibition mechanisms. Mol Divers. 2011, 15 (2): 305-316.View Article
- Supuran CT, Fiore AD, Alterio V, Monti SM, Simone GD: Recent Advances in Structural Studies of the Carbonic Anhydrase Family: The Crystal Structure of Human CA IX and CA XIII. Curr Pharm Des. 2010, 16: 3346-3254.
- Supuran CT: Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008, 7 (2): 168-181.View Article
- Supuran CT, Scozzafava A: Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem. 2007, 15 (13): 4336-4350.View Article
- Ladbury JE, Klebe G, Freire E: Adding calorimetric data to decision making in lead discovery: a hot tip. Nat Rev Drug Discov. 2010, 9: 23-27.View Article
- Lehtonen J, Shen B, Vihinen M, Casini A, Scozzafava A, Supuran CT, Parkkila AK, Saarnio J, Kivela AJ, Waheed A, Sly WS, Parkkila S: Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J Biol Chem. 2004, 279 (4): 2719-2727.View Article
- Fiore AD, Monti SM, Hilvo M, Parkkila S, Romano V, Scaloni A, Pedone C, Scozzafava A, Supuran CT, Simone GD: Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. Proteins. 2009, 74: 164-175.View Article
- Lehtonen JM, Parkkila S, Vullo D, Casini A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design. Bioorg Med Chem Lett. 2004, 14 (14): 3757-3762.View Article
- Vernier W, Chong W, Rewolinski D, Greasley S, Pauly T, Shaw M, Dinh D, Ferre RA, Nukui S, Ornelas M, Reyner E: Thioether benzenesulfonamide inhibitors of carbonic anhydrases II and IV: structure-based drug design, synthesis, and biological evaluation. Bioorg Med Chem. 2010, 18 (9): 3307-3319.View Article
- Capkauskaite E, Baranauskiene L, Golovenko D, Manakova E, Grazulis S, Tumkevicius S, Matulis D: Indapamide-like benzenesulfonamides as inhibitors of carbonic anhydrases I, II, VII, and XIII. Bioorg Med Chem. 2010, 18 (21): 7357-7364.View Article
- Sudzius J, Baranauskiene L, Golovenko D, Matuliene J, Michailoviene V, Torresan J, Jachno J, Sukackaite R, Manakova E, Grazulis S, Tumkevicius S, Matulis D: 4-[N-(substituted 4-pyrimidinyl)amino]benzenesulfonamides as inhibitors of carbonic anhydrase isozymes I, II, VII, and XIII. Bioorg Med Chem. 2010, 18 (21): 7413-7421.View Article
- Khalifah RG, Zhang F, Parr JS, Rowe ES: Thermodynamics of binding of the CO2-competitive inhibitor imidazole and related compounds to human carbonic anhydrase I: an isothermal titration calorimetry approach to studying weak binding by displacement with strong inhibitors. Biochemistry. 1993, 32 (12): 3058-3066.View Article
- Baker BM, Murphy KP: Evaluation of linked protonation effects in protein binding reactions using isothermal titration calorimetry. Biophys J. 1996, 71 (4): 2049-2055.View Article
- Krishnamurthy VM, Kaufman GK, Urbach AR, Gitlin I, Gudiksen KL, Weibel DB, Whitesides GM: Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem Rev. 2008, 108 (3): 946-1051.View Article
- Velazquez Campoy A, Freire E: ITC in the post-genomic era…? Priceless. Biophys Chem. 2005, 115 (2–3): 115-124.View Article
- Velazquez-Campoy A, Freire E: Isothermal titration calorimetry to determine association constants for high-affinity ligands. Nat Protoc. 2006, 1: 186-191.View Article
- Matulis D, Kranz JK, Salemme FR, Todd MJ: Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry. 2005, 44 (13): 5258-5266.View Article
- Mezzasalma TM, Kranz JK, Chan W, Struble GT, Schalk-Hihi C, Deckman IC, Springer BA, Todd MJ: Enhancing recombinant protein quality and yield by protein stability profiling. J Biomol Screen. 2007, 12 (3): 418-428.View Article
- Zubriene A, Matuliene J, Baranauskiene L, Jachno J, Torresan J, Michailoviene V, Cimmperman P, Matulis D: Measurement of Nanomolar Dissociation Constants by Titration Calorimetry and Thermal Shift Assay - Radicicol Binding to Hsp90 and Ethoxzolamide Binding to CAII. Int J Mol Sci. 2009, 10 (6): 2662-2680.View Article
- Kranz JK, Schalk-Hihi C: Protein thermal shifts to identify low molecular weight fragments. Methods Enzymol. 2011, 493: 277-298.View Article
- Zubriene A, Kazlauskas E, Baranauskiene L, Petrauskas V, Matulis D: Isothermal titration calorimetry and thermal shift assay in drug design. European pharmaceutical review. 2011, 16: 56-59.
- Cimmperman P, Matulis D: Protein thermal denaturation measurements via a fluorescent dye. 2011, RSC Publishing, 247-274. chap. 8
- Baranauskiene L, Hilvo M, Matuliene J, Golovenko D, Manakova E, Dudutiene V, Michailoviene V, Torresan J, Jachno J, Parkkila S, Maresca A, Supuran CT, Grazulis S, Matulis D: Inhibition and binding studies of carbonic anhydrase isozymes I, II and IX with benzimidazo[1,2-c][1,2,3]thiadiazole-7-sulphonamides. J Enzyme Inhib Med Chem. 2010, 25 (6): 863-870.View Article
- Cimmperman P, Baranauskiene L, Jachimoviciute S, Jachno J, Torresan J, Michailoviene V, Matuliene J, Sereikaite J, Bumelis V, Matulis D: A quantitative model of thermal stabilization and destabilization of proteins by ligands. Biophys J. 2008, 95 (7): 3222-3231.View Article
- Matulis D, Todd MJ: Thermodynamics - Structure Correlations of Sulfonamide Inhibitor Binding to Carbonic Anhydrase. 2004, Wiley, 107-132.
- Remko M, von der Lieth CW: Theoretical study of gas-phase acidity, pKa, lipophilicity, and solubility of some biologically active sulfonamides. Bioorg Med Chem. 2004, 12 (20): 5395-5403.View Article
- Innocenti A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Inhibition of transmembrane isoforms IX, XII, and XIV with less investigated anions including trithiocarbonate and dithiocarbamate. Bioorg Med Chem Lett. 2010, 20 (5): 1548-1550.View Article
- Thiry A, Ledecq M, Cecchi A, Frederick R, Dogne JM, Supuran CT, Wouters J, Masereel B: Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009, 17 (2): 553-557.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.